Emergent Biosolutions (EBS)

• Market cap: $415M
• 1 day: 0.25%
• 5 days: -2.55%
• 1 month: -27.02%
• 3 months: -35.43%
• 6 months: -2.31%
• Year to date: -35.89%
• 1 year: 37.33%
• 5 years: -91.18%
• 10 years: -75.14%
• Sector: Healthcare
• Industry: Drug Manufacturers - Specialty & Generic

About: Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.

Employees: 900